Biopharmaceutical Contract Manufacturing Market, 2015 - 2025

Biopharmaceutical Contract Manufacturing Market, 2015 - 2025

INTRODUCTION

Characterized by a rapidly expanding product pipeline and a capital intensive manufacturing business, the biopharmaceutical market is witnessing a growing trend towards contract manufacturing. In addition to serving as a cost-cutting tool, contract manufacturing provides several other advantages to biopharmaceutical companies including technical expertise, operational efficiency, regulatory support and the ability to focus on core competencies. Spanning multiple operations within the wider manufacturing processes, outsourcing is increasingly being viewed as a strategic imperative.

The current marketplace has the presence of over 160 biopharmaceutical CMOs, offering a multitude of services ranging from cell line development and API manufacturing to fill/ finish of the product. Lonza, Boehringer Ingelheim and FUJIFILM Diosynth Biotechnologies are amongst the leading companies in this market. In addition, there are several key players operating in emerging regions that contribute significantly to this market; examples include Kemwell Biopharma (India), Shasun Pharma (India) and WuXi AppTec (China).

Despite being surrounded with several challenges associated with cost and complexity in bio-manufacturing, the contract manufacturing market has witnessed considerable growth in the past few years. Driven by the strong growth in the biologics market and advancement in technologies, biopharmaceutical contract manufacturing is well positioned to achieve an accelerated growth in the coming years. An intensive framework of collaborations and investment activity further supports the optimistic growth outlook.

SCOPE OF THE REPORT

The ‘Biopharmaceutical Contract Manufacturing Market, 2015 - 2025’ report provides an extensive study of the contract manufacturing market for biopharmaceuticals. With biotechnology industry striving to maximize profits, outsourcing has emerged as an ever increasing trend. The study presents an in-depth analysis of a diverse set of biopharmaceutical CMOs on some of the key parameters such as geographical location, scale of operation, type of biologics manufactured, expression systems, type of bioreactors used and fermentation capacity. In addition, it captures some of the potential growth areas which will likely present tremendous opportunities for biopharmaceutical CMOs and ensure an accelerated pace of growth. Some of the niche service areas include manufacturing of ADCs and bispecific antibodies. Specifically, these markets typify huge unmet manufacturing requirements and represent untapped areas of targeted therapy revenue making outsourcing an attractive option.

The report assesses the key drivers that have governed the evolution of biopharmaceutical contract manufacturing market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity for biopharmaceutical CMOs market over the next decade, segmented on the basis of business operations, type of expression systems and key regions.

In addition, the study provides information on some of the most important aspects of biopharmaceutical outsourcing; these include growing collaborations, investment activity, technological advancements and development of biosimilars. In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples include quality concerns, stringent regulations and lack of funding. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run.

The base year for the report is 2014; the report provides market forecasts for the period 2015 - 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

EXAMPLE HIGHLIGHTS

1. North America and Europe are the predominant regions where majority of the production facilities of biopharmaceutical CMOs are located. Of the 160 CMOs we studied, 80 have presence in multiple locations in the US. In Europe, the other major hub for CMOs, Germany and the UK have presence of over 20 CMOs. Companies have also gradually moved their focus to developing countries in order to take advantage of the relatively lower costs.

2. With respect to the bio-manufacturing capabilities of contract manufacturers, majority of the CMOs currently are capable of manufacturing proteins and antibodies; mammalian based manufacturing represents the predominantly used production method and will continue to achieve a relatively higher growth rate.

3. In terms of analysis by scale of operation, majority of the biopharmaceutical CMOs have the capability to operate on clinical as well as commercial scale. Out of 153 CMOs evaluated for this exercise, over 70% have the provision for both clinical and commercial stage manufacturing.

4. Although the ‘one stop shop’ model is steadily gaining pace in the biopharmaceutical CMO industry, certain operations are witnessing an increased extent of outsourcing. Fill/ finish operations represents one of the most heavily outsourced operations; owing to the requirement of specialized technologies and technical expertise, this segment is projected to be outsourced significantly in the near future.

5. Certain niche segments within bio-manufacturing which have garnered the interest of biopharmaceutical CMOs include manufacturing of ADCs, bispecific antibodies and gene therapy; these markets, characterized by an untapped potential and optimistic growth prospects will continue to benefit from an increasing presence of CMOs. In addition, the emerging biosimilars industry represents another key demand sector for biopharmaceutical CMOs.

6. The highly competitive market landscape is abuzz with an intensive framework of growing investment activities and collaborations. In addition, technological advancements including the use of disposable technologies is another key bio-manufacturing trend that is emblematic of the current market intensity.

7. Driven by the rapidly expanding biopharmaceutical market and technological advancements, we expect the overall market to grow at an annualized rate of 8.3%. The rate of growth is likely to vary significantly across different segments / activities and across geographical regions.

RESEARCH METHODOLOGY

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. Introduction
3.1. Context and Background
3.2. Biopharmaceuticals: An Overview
3.3. Manufacturing of Biopharmaceuticals
3.4. Expression Systems
3.4.1. Bacterial Protein ExpressionSystem
3.4.2. Yeast Protein Expression System
3.4.3. Mammalian Protein Expression System
3.4.4. Insect Protein Expression System
3.4.5. Plant Protein Expression System
3.5. Need for Biopharmaceutical Outsourcing
3.6. Commonly Outsourced Biomanufacturing Activities
3.7. Selection of Biopharmaceutical CMOs
4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING: DEVELOPED REGIONS
4.1. Chapter Overview
4.2. The Evolution of Biopharmaceutical Contract Manufacturing
4.3. Biopharmaceutical Outsourcing in the US
4.3.1. The Draft Guidance: Contract Manufacturing Arrangements for Drugs - Quality Agreements
4.3.1.1. Definition of ‘Who’ and ‘What’ of Contract Manufacturing
4.3.1.2. Quality Agreement
4.3.2. US Biopharmaceutical CMOs: Overview and Capabilities
4.3.2.1. Patheon
4.3.2.1.1. Company Overview
4.3.2.1.2. Financial Performance
4.3.2.1.3. Services
4.3.2.1.4. Partnerships
4.3.2.1.5. Expansions
4.3.2.1.6. Other Developments
4.3.2.1.7. Future Outlook
4.3.2.2. Catalent
4.3.2.2.1. Company Overview
4.3.2.2.2. Financial Performance
4.3.2.2.3. Services
4.3.2.2.4. Partnerships
4.3.2.2.5. Approvals
4.3.2.2.6. Expansions
4.3.2.2.7. Future Outlook
4.3.2.3. Baxter BioPharma Solutions
4.3.2.3.1. Company Overview
4.3.2.3.2. Financial Performance
4.3.2.3.3. Services
4.3.2.3.4. Partnerships
4.3.2.3.5. Expansions
4.3.2.4. AMRI
4.3.2.4.1. Company Overview
4.3.2.4.2. Financial Performance
4.3.2.4.3. Services
4.3.2.4.4. Expansions
4.3.2.4.5. Future Outlook
4.3.2.5. Cytovance Biologics
4.3.2.5.1. Company Overview
4.3.2.5.2. Services
4.3.2.5.3. Partnerships
4.3.2.5.4. Expansions
4.3.2.5.5. Other Developments
4.3.3. The US: Biopharmaceutical Sub-Market Forecast, 2015-2025
4.3.3.1. The US Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
4.3.3.2. The US Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems
4.4. Biopharmaceutical Outsourcing in Europe
4.4.1. Biopharmaceutical Outsourcing: US vs. Europe
4.4.2. EMA’s cGMP Regulations
4.4.3. European Biopharmaceutical CMOs: Overview and Capabilities
4.4.3.1. Boehringer Ingelheim BioXcellence
4.4.3.1.1. Company Overview
4.4.3.1.2. Financial Performance
4.4.3.1.3. Services
4.4.3.1.4. Partnerships
4.4.3.1.5. Expansions
4.4.3.1.6. Future Outlook
4.4.3.2. Lonza
4.4.3.2.1. Company Overview
4.4.3.2.2. Financial Performance
4.4.3.2.3. Services
4.4.3.2.4. Partnerships
4.4.3.2.5. Expansions
4.4.3.2.6. Future Outlook
4.4.3.3. FUJIFILM Diosynth Biotechnologies
4.4.3.3.1. Company Overview
4.4.3.3.2. Financial Performance
4.4.3.3.3. Services
4.4.3.3.4. Partnerships
4.4.3.3.5. Expansions
4.4.3.3.6. Developments
4.4.3.3.7. Future Outlook
4.4.3.4. Rentschler Biotechnologie
4.4.3.4.1. Company Overview
4.4.3.4.2. Services
4.4.3.4.3. Expansions
4.4.3.4.4. Future Outlook
4.4.3.5. Celonic
4.4.3.5.1. Company Overview
4.4.3.5.2. Services
4.4.3.5.3. Partnerships
4.4.3.5.4. Expansions
4.4.3.5.5. Developments
4.4.4. Europe: Biopharmaceutical Sub-Market Forecast, 2015-2025
4.4.4.1. Europe Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
4.4.4.2. Europe Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems
4.4.4.3. Europe Biopharmaceutical CMO Market Forecast: Distribution by Country
4.5. Japan: A New and Promising Player
4.6. Comparison of Regulatory Landscape in Developed Nations
4.6.1. Requirement of Written Quality Agreements
4.6.2. Regulatory Considerations During Clinical Development
5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING: EMERGING REGIONS
5.1. Chapter Overview
5.2. Biopharmaceutical Contract Manufacturing in China
5.2.1. Regulatory Scenario in China
5.2.2. Challenges Faced by Chinese Biopharmaceutical CMOs
5.2.3. Growing Investments in Biopharmaceutical Contract Manufacturing in China
5.2.4. Chinese Biopharmaceutical CMOs: Overview and Capabilities
5.2.4.1. AutekBio
5.2.4.2. WuXi AppTec
5.2.5. China: Biopharmaceutical Sub-Market Forecast, 2015-2025
5.2.5.1. Chinese Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
5.2.5.2. Chinese Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems
5.3. Biopharmaceutical Contract manufacturing in India
5.3.1. Regulatory Scenario in India
5.3.2. Challenges Faced by Indian Biopharmaceutical CMOs
5.3.3. Indian Biopharmaceutical CMOs: Overview and Capabilities
5.3.3.1. Kemwell Biopharma
5.3.3.2. Shasun Pharma
5.3.3.3. Intas Pharmaceuticals
5.3.3.4. Syngene
5.3.3.5. Piramal Healthcare Pharma Solutions
5.3.13. India: Biopharmaceutical Sub-Market Forecast, 2015-2025
5.3.13.1. Indian Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
5.3.13.2. Indian Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems
6. COMPETITIVE LANDSCAPE
6.1. Chapter Overview
6.2. Biopharmaceutical CMOs: Regional Analysis
6.3. Biopharmaceutical CMOs: Analysis by Scale of Operation
6.4. Biopharmaceutical CMOs: Capability Analysis
6.4.1. Distribution by Type of Biologic Molecule
6.4.2. Distribution By Expression Systems
6.5. Biopharmaceutical CMOs: Type of Bioreactor
7. NICHE SECTORS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING
7.1. Chapter Overview
7.2. Antibody Drug Conjugates (ADCs)
7.2.1. A Healthy Pipeline Demands In-House or Contract Manufacturing Capabilities
7.2.2. Limited Number of Companies are Providing ADC Technology
7.2.3. Steps Involved in Manufacturing an ADC
7.2.4. Challenges Facing the ADC Manufacturers
7.2.5. Extent of In-house Manufacturing
7.2.6. Presence of Contract Manufacturers
7.2.6.1. Linkers
7.2.6.2. Cytotoxins
7.2.6.3. Conjugation
7.2.7. CMOs Investing to Increase Their ADC Capabilities Enabling Them to Tap the Growing Demand for Contract Manufacturing
7.2.8. Contract Manufacturers Collaborating to Provide ADC Capabilities
7.3. Bispecific Antibody Therapeutics
7.3.1. The Bispecific Advantage
7.3.2. Bispecific Antibody Formats
7.3.3. A Healthy Pipeline of Bispecific Antibodies Has Drugs Spread Across Different Phases of Clinical Development
7.3.4. Bispecific Antibody Production: Technology Providers
7.3.5. Presence of Contract Manufacturers
7.4. Gene Therapy
7.4.1. A Highly Populated Pipeline Demands Appropriate Manufacturing Capabilities
8. OUTSOURCING OF BIOSIMILARS
8.1. Chapter Overview
8.2. Biosimilars: An Overview
8.3. Need for Outsourcing Biosimilars
8.4. Impact of Biosimilars on the CMOs
8.5. Biosimilars to Drive Cost Effectiveness
8.6. Presence of CMOs and CROs in the Biosimilars Market
9. RECENT DEVELOPMENTS
9.1. Chapter Overview
9.2. CMO Investments in New Facilities and Facility Expansions
9.2.1. Growing Number of Investments Over the Years
9.2.2. FUJIFILM Diosynth Biotechnologies Leads the Investments Activity
9.2.3. Distribution of Investments by Type
9.3. Deals and Partnerships
9.3.1. Analysis by Type of Partnership
9.3.2. Growing Trend of Partnerships
9.4. Technological Advancements
9.4.1. Adoption of Single-use Technologies
9.4.2. Process Analytical Technology
9.4.3. Continuous Processing
9.4.4. Quality by Design in Bio-processing
10. MARKET SIZING AND FORECAST
10.1. Context and Background
10.2. Outsourcing in Biopharmaceutical Industry
10.3. Forecast Methodology
10.4. Biopharmaceutical API Contract Manufacturing Market, 2015 - 2025
10.5. Biopharmaceutical FDF Contract Manufacturing Market, 2015 - 2025
10.6. Overall Biopharmaceutical Contract Manufacturing Market, 2015 - 2025
10.7. Biopharmaceutical Contract Manufacturing Market: Distribution By Expression Systems
10.8. Biopharmaceutical Contract Manufacturing Market: Distribution By Region
11. FUTURE OF BIOPHARMACEUTICAL CMO MARKET
11.1. Chapter Overview
11.2. Technological Developments to Drive Growth
11.3. Focus on Niche Segments
11.4. Biosimilars: A Major opportunity for CMOs
11.5. Growing Demand to Spur Investment Activity
11.6. Outsourcing Budgets on Rise
11.7. Shift Towards aStrategic Partnering
11.8. CMOs May Face Capacity Fluctuations
11.9. Focus on Emerging Markets
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
13. INTERVIEW TRANSCRIPTS
13.1. Interview 1: FUJIFILM Diosynth Biotechnologies,
Stephen Taylor, Senior Vice President Commercial
13.2. Interview 2: Goodwin Biotechnology,
David C. Cunningham, Director of Marketing and Communications
13.3. Interview 3: Rentschler Biotechnologie
Dr. Birgit Schwab, Senior Manager Strategic Marketing
13.4. Interview 4: Piramal Healthcare
Dr. Mark Wright, Site Head, Grangemouth
13.5. Interview 5: Catalent Pharma Solutions
Stacy McDonald, Group Product Manager &
Jennifer L. Mitcham, Director - Business Development
13.6. Interview 6: Novasep Synthesis
Kevin Daley, Market Director Pharmaceuticals
14. CONCLUSION
14.1. Biomanufacturing: A Profitable Segment for CMOs
14.2. Key Industry Drivers and Challenges
14.3. US and Europe will Remain the Key Manufacturing Sites
14.4. A Multi-billion Dollar Rapidly Expanding Market
14.5. Concluding Remarks
15. APPENDICES
16. LIST OF COMPANIES
LIST OF FIGURES
Figure 3.1 Types of Expression Systems
Figure 3.2 Commonly Outsourced Biomanufacturing Operations
Figure 4.1 US Biopharmaceutical Contract Manufacturing Market: Growth Drivers and Challenges
Figure 4.2 Patheon: Service Portfolio
Figure 4.3 Patheon: Revenues, 2009 – 2013 (USD million)
Figure 4.4 Patheon: Revenues by Business Divisions (USD million)
Figure 4.5 Patheon: Revenue Break-up for CMO (USD million, Percentage)
Figure 4.6 Catalent: Service Portfolio
Figure 4.7 Catalent: Revenues, 2010 – 2014 (USD million)
Figure 4.8 Catalent: Revenues by Business Divisions, 2014 (USD million)
Figure 4.9 Baxter BioPharma Solutions: Service Portfolio
Figure 4.10 Baxter Biopharma Solutions: Revenues, 2011 – 2014 (USD million)
Figure 4.11 AMRI: Service Portfolio
Figure 4.12 AMRI: Revenues, 2010 – 2014 (USD million)
Figure 4.13 AMRI: Revenues by Business Divisions, 2014 (USD million)
Figure 4.14 Cytovance Biologics: Service Portfolio
Figure 4.15 US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Figure 4.16 US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Figure 4.17 European Biopharmaceutical Contract Manufacturing Market: Growth Drivers and Challenges
Figure 4.18 BioXcellence: Service Portfolio
Figure 4.19 Boehringer Ingelheim: Revenues, 2009 – 2013 (EUR million)
Figure 4.20 Boehringer Ingelheim: Revenues by Business Divisions (EUR million)
Figure 4.21 Lonza: Service Portfolio
Figure 4.22 Lonza: Revenues, 2010 – 2014 (CHF million)
Figure 4.23 Lonza: Revenues by Business Divisions, 2014 (CHF million)
Figure 4.24 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 4.25 FUJIFILM Group: Revenues, 2010 – 2014 (JPY billion)
Figure 4.26 FUJIFILM Holdings: Revenues by Business Divisions, 2014 (JPY billion)
Figure 4.27 Rentschler Biotechnologie: Service Portfolio
Figure 4.28 Celonic: Service Portfolio
Figure 4.29 Europe Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Figure 4.30 Europe Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Figure 4.31 Europe Biopharmaceutical CMO Market: Distribution by EU5 Countries
Figure 4.32 Europe Biopharmaceutical CMO Market by Country, 2015-2025: Base Scenario (USD billion)
Figure 5.1 Chinese CMO Market: Growth Drivers
Figure 5.2 AutekBio: Service Portfolio
Figure 5.3 Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Figure 5.4 Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Figure 5.5 Indian CMO Market: Growth Drivers
Figure 5.6 Kemwell Biopharma: Partnerships and Expansions
Figure 5.7 Shasun Pharma: Revenues by Geography, 2013-14 (INR billion)
Figure 5.8 Biocon: Revenues by Business Divisions: 2014 (INR million)
Figure 5.9 Piramal: Partnerships and Investments
Figure 5.10 Indian Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Figure 5.11 Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Figure 6.1 Biopharmaceutical CMOs: Geographical Location
Figure 6.2 Biopharmaceutical CMOs: Regional Distribution
Figure 6.3 Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 6.4 Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Figure 6.5 Biopharmaceutical CMOs: Distribution by Expression Systems
Figure 6.6 Single Use Bioreactors: Advantages and Disadvantages
Figure 7.1 Companies Active in the ADC Market: Number of Molecules in Development (Clinical and Marketed)
Figure 7.2 Bispefic Antibody Pipeline Analysis: By Phase of Development
Figure 7.3 Gene Therapy Pipeline Analysis: By Phase of Development
Figure 7.4 Contract Manufacturing in Gene Therapy: By Capability
Figure 7.5 Contract Manufacturing in Gene Therapy: By Location
Figure 8.1 Biosimilars: Definition
Figure 9.1 Biopharmaceutical CMOs: Cumulative Investments by Year, 2009-2014
Figure 9.2 Biopharmaceuticals: Leading players by Investments
Figure 9.3 Distribution of Investments by Type
Figure 9.4 Biopharmaceuticals Agreements: Distribution by Type of Partnership
Figure 9.5 Biopharmaceuticals: Cumulative Partnerships by Year, Pre 2010 - 2014
Figure 9.6 Process Analytical Technology: Advantages
Figure 9.7 Continuous Processing: Key Advantages
Figure 10.1 Outsourced Segments in Biopharmaceutical Industry
Figure 10.2 Biopharmaceutical API Manufacturing Market, 2015 – 2025: Base Scenario (USD billion)
Figure 10.3 Biopharmaceutical FDF Manufacturing Market, 2015 – 2025: Base Scenario (USD billion)
Figure 10.4 Overall Biopharmaceutical Contract Manufacturing Market by Type of Business Operation, 2015 – 2025: Base Scenario (USD billion)
Figure 10.5 Overall Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Figure 10.6 Biopharmaceutical Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2025
Figure 12.1 Numbers of Biologics Approved by the USFDA, 2009-2014
Figure 12.2 Top Selling Biologics: Estimated Patent Expiry
Figure 14.1 Biopharmaceutical Contract Manufacturing: Key Growth Drivers and Challenges
Figure 14.2 Biopharmaceutical Contract Manufacturing Market (USD Billion) Forecast: 2015, 2020 and 2025
LIST OF TABLES
Table 4.1 Patheon: Capacity for Sterile Formulations Filling
Table 4.2 Patheon: Facility Sites and Segments
Table 4.3 Catalent: Manufacturing and Laboratory Facilities
Table 4.4 Baxter BioPharma Solutions: Facility Sites and Manufacturing Services
Table 4.5 AMRI: Manufacturing and Laboratory Facilities
Table 4.6 FDA’s Quality Agreement vs EMA’s cGMP Regulations: Comparison
Table 4.7 BioXcellence: Facility Sites and Manufacturing Functions
Table 4.8 Lonza: Custom Development and Custom Manufacturing Sites
Table 4.9 Lonza: Mammalian Biopharmaceutical Facilities along with their Scale of Operation and Capacities
Table 4.10 FUJIFILM Diosynth: Upstream Capacity and Downstream Capabilities
Table 4.11 FUJIFILM Diosynth: Upstream Capacity in Mammalian Cell Culture
Table 4.12 Celonic: Custom Development and Custom Manufacturing Sites
Table 5.1 Kemwell Biopharma: Facility Sites and their Functions
Table 5.2 Shasun: Facility Sites and their Functions
Table 5.3 Intas: Facility Sites and their Functions
Table 5.4 Piramal: Facility Sites and their Functions
Table 6.1 Biopharmaceutical CMOs: Scale of Operation
Table 6.2 Biopharmaceutical CMOs: Type of Biologics
Table 6.3 Biopharmaceutical CMOs: Analysis by Expression Systems
Table 6.4 Biopharmaceutical CMOs: Analysis by Type of Bioreactor
Table 7.1 ADC Molecules in Preclinical Development/Discovery Phase
Table 7.2 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 7.3 ADC CMOs: Investments
Table 7.4 ADC CMOs: Partnerships
Table 7.5 List of Bispecific Antibodies in Preclinical Development/ Discovery Stage
Table 7.6 Bispecific Antibodies: List of Technology Platforms
Table 7.7 Contract Manufacturing Organisations with Bispecific Antibody Capabilities: Screening, Expression or Purification
Table 7.8 Contract Manufacturers in Gene Therapy
Table 8.1 Contract Service Providers in Biosimilars
Table 9.1 Biopharmaceutical CMOs: Investments, 2009-2014
Table 9.2 Biopharmaceutical CMOs: Deals and Partnerships, 2004-2014
Table 12.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Table 14.1 Patheon: Revenues, 2009-2013 (USD million)
Table 14.2 Patheon: Revenues by Business Divisions (USD million)
Table 14.3 Patheon: Revenue Break-up for CMO, 2013 (USD million, Percentage)
Table 14.4 Catalent: Revenues, 2010 – 2014 (USD million)
Table 14.5 Catalent: Revenues by Business Divisions, 2014 (USD million)
Table 14.6 Baxter Biopharma Solutions: Revenues, 2011-2014 (USD million)
Table 14.7 AMRI: Revenues, 2010 – 2014 (USD million)
Table 14.8 AMRI: Revenues by Business Divisions, 2014 (USD million)
Table 14.9 US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Table 14.10 US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Conservative Scenario (USD billion)
Table 14.11 US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
Table 14.12 US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Table 14.13 US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
Table 14.14 US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
Table 14.15 Boehringer Ingelheim: Revenues, 2009-2013 (EUR million)
Table 14.16 Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)
Table 14.17 Lonza: Revenues, 2010 – 2014 (CHF Million)
Table 14.18 Lonza: Revenues by Business Divisions, 2014 (CHF million)
Table 14.19 FUJIFILM Group: Revenues, 2010 – 2014 (JPY Billion)
Table 14.20 Fujifilm Group: Revenues by Business Divisions, 2014 (JPY Billion)
Table 14.21 Europe: Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Table 14.22 Europe: Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Conservative Scenario (USD billion)
Table 14.23 Europe Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
Table 14.24 Europe: Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Table 14.25 Europe: Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
Table 14.26 Europe: Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
Table 14.27 Europe Biopharmaceutical CMO Market: Distribution by Countries
Table 14.28 Europe Biopharmaceutical CMO Market by Country, 2015-2025: Base Scenario (USD billion)
Table 14.29 Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Table 14.30 Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Conservative Scenario (USD billion)
Table 14.31 Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
Table 14.32 Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Table 14.33 Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
Table 14.34 Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
Table 14.35 Shasun Pharma: Revenues by Geography, 2013-14 (INR million)
Table 14.36 Biocon Revenues by Business Segments: 2014 (INR million)
Table 14.37 Indian Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
Table 14.38 Indian Biopharmaceutical CMO Market by Type by Business Operation, 2015-2025: Conservative Scenario (USD billion)
Table 14.39 Indian Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
Table 14.40 Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
Table 14.41 Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
Table 14.42 Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
Table 14.43 Biopharmaceutical CMOs: Regional Distribution
Table 14.44 Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 14.45 Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Table 14.46 Biopharmaceutical CMOs: Distribution by Expression Systems
Table 14.47 Biopharmaceutical CMOs: Analysis by Type of Bioreactor
Table 14.48 Companies Active in the ADC Market: Number of Molecules in Development (Clinical and Marketed)
Table 14.49 Bispecific Antibody Market, Pipeline Drugs: By Phase of Development
Table 14.50 Gene Therapy Pipeline Analysis: Distribution by Phase of Development
Table 14.51 Contract Manufacturing in Gene Therapy: By Capability
Table 14.52 Contract Manufacturing in Gene Therapy: By Location
Table 14.53 Biopharmaceutical CMOs: Cumulative Investments by Year, 2009-2014
Table 14.54 Biopharmaceuticals: Leading players by Investments
Table 14.55 Distribution of Investments by Type
Table 14.56 Biopharmaceuticals: Distribution by Type of Partnership
Table 14.57 Biopharmaceuticals: Cumulative Partnerships by Year, Pre 2010 - 2014
Table 14.58 Biopharmaceutical API Manufacturing Market, 2015 – 2025: Base Scenario (USD billion)
Table 14.59 Biopharmaceutical API Manufacturing Market, 2015 – 2025: Conservative Scenario (USD billion)
Table 14.60 Biopharmaceutical API Manufacturing Market, 2015 – 2025: Optimistic Scenario (USD billion)
Table 14.61 Biopharmaceutical FDF Manufacturing Market, 2015 – 2025: Base Scenario (USD billion)
Table 14.62 Biopharmaceutical FDF Manufacturing Market, 2015 – 2025: Conservative Scenario (USD billion)
Table 14.63 Biopharmaceutical FDF Manufacturing Market, 2015 – 2025: Optimistic Scenario (USD billion)
Table 14.64 Overall Biopharmaceutical Contract Manufacturing Market, 2015 – 2025: Base Scenario (USD billion)
Table 14.65 Overall Biopharmaceutical Contract Manufacturing Market, 2015 – 2025: Conservative Scenario (USD billion)
Table 14.66 Overall Biopharmaceutical Contract Manufacturing Market, 2015 – 2025: Optimistic Scenario (USD billion)
Table 14.67 Overall Biopharmaceutical Contract Manufacturing Market: Distribution by Expression Systems, 2015-2025: Base Scenario (USD billion)
Table 14.68 Overall Biopharmaceutical Contract Manufacturing Market: Distribution by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
Table 14.69 Overall Biopharmaceutical Contract Manufacturing Market: Distribution by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
Table 14.70 Biopharmaceutical Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2025
Table 14.71 Numbers of Biologics Approved by the USFDA, 2009-2014

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook